Astrana Health Inc (ASTH)vsEli Lilly and Company (LLY)
ASTH
Astrana Health Inc
$37.99
+0.37%
HEALTHCARE · Cap: $1.87B
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1949% more annual revenue ($72.25B vs $3.53B). LLY leads profitability with a 35.0% profit margin vs 0.9%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
ASTH
Buy56
out of 100
Grade: C
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.9%
Fair Value
$188.57
Current Price
$37.99
$150.58 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.6% year-over-year
Earnings expanding 110.1% YoY
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.8% — below average capital efficiency
0.9% margin — thin
Operating margin of 3.0%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ASTH
The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 55.6% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ASTH
The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 61.7x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
ASTH profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
ASTH carries more volatility with a beta of 0.99 — expect wider price swings.
ASTH is growing revenue faster at 55.6% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 56/100), backed by strong 35.0% margins and 55.5% revenue growth. ASTH offers better value entry with a 89.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Astrana Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?